Activation of NF-κB plays a critical role in the pathophysiology of
R. rickettsii infection by ensuring the survival of infected host cells to allow for the continued growth and replication of intracellular bacteria (
3,
22). A particularly intriguing aspect of
Rickettsia-induced NF-κB activation is that it occurs in two distinct phases during infection of cultured ECs (
37); there is also a possibility that differences may exist in the upstream signaling mechanisms contributing to this biphasic pattern. The goal of the present study was to define changes in the mRNA and protein expression of major NF-κB subunits, degradation of IκB proteins, and activation of catalytic components of the IκB kinase complex, a cytoplasmic signalosome responsible for the phosphorylation of IκBα and/or IκBβ.
Although NF-κB is known to participate in its own regulation by partially regulating the expression of the human p105/p50 gene promoter (
48), the steady-state mRNA of p105 and protein levels of p50 in
Rickettsia-infected cells remained relatively unaltered. This suggests that de novo transcription via autoregulatory or other transcription factors (e.g., AP1 and SP1) does not take place during the course of infection. It also indicates that infection did not affect the processing of the p105 precursor to the active p50 form. Similar to other cell types, p65 was expressed constitutively, and
R. rickettsii infection did not appear to alter its expression profile. That the p65 promoter contains at least three functional sites for the transcription factor SP1 upstream of the initiation site, but none for NF-κB (
48,
49), provides further indirect evidence for noninvolvement of SP1-mediated transcriptional events and supports the notion that SP1 is not activated during
R. rickettsii infection (L. A. Sporn and S. K. Sahni, unpublished observations).
The IκB family proteins can differentially associate with and regulate the activity of various NF-κB dimers in the cytoplasm. The targeted degradation of these proteins is critical to all known mechanisms of NF-κB activation. In
R. rickettsii-infected ECs, the early peak of NF-κB DNA-binding activity coincided with increased IκBα mRNA levels and was preceded by increased phosphorylation of IκBα (Fig. and ). Lower levels of total protein further indicate concurrent degradation of phosphorylated IκBα (Fig. ). This is in agreement with our earlier findings that inhibition of proteasomal IκBα degradation via MG132 or MG115 or expression of a dominant-negative IκBα can effectively inhibit the early phase of
Rickettsia-induced NF-κB in ECs or fibroblasts, respectively (
3,
31). The failure to accumulate IκBα back to basal levels at all times despite evidence for increased mRNA expression suggests the involvement of continued IκBα degradation, at least in part, in the late phase of NF-κB activation. It is possible that other unknown mechanisms governing posttranscriptional modifications to either inhibit or downregulate the resynthesis of IκBα, which are known to occur during cytomegalovirus infection of monocytes (
50) and respiratory syncytial virus infection of A549 cells (
21), may also be involved.
In spite of significant sequence homology and ability to interact with the same set of NF-κB proteins, IκBα and IκBβ display distinct responses to different inducers. Persistent NF-κB activation by soluble agonists (e.g., LPS and IL-1), infection with pathogenic bacteria (
Listeria), and pathogen-derived mediators (Tax protein of human T-cell leukemia virus type 1) usually involve prolonged activation of NF-κB by binding to hypophosphorylated IκBβ or inactivation of IκBβ (
15,
28,
39). We observed only subtle changes in the mRNA and protein expression levels of IκBβ at all times tested in the present study, suggesting that it does not contribute appreciably to NF-κB activation during
R. rickettsii infection. IκB

, another member of the IκB family, associates predominantly with p65 homodimers or p65-cRel heterodimers in the cytoplasm but not with p50 containing heterodimers. It has been proposed that specific interactions of IκB

with c-Rel dimers play a functional role in the induction of expression of adhesion molecules in vascular ECs (
36), and degradation of both IκBα and IκB

to various degrees occurs during infection of different intestinal ECs with enteroinvasive bacteria (
7). Although
R. rickettsii infection of ECs triggers nuclear translocation of p65 without affecting c-Rel (
37), a possibility which remains to be investigated is that the degradation of IκB

associated with p65 (RelA) homodimers may contribute to the second phase of NF-κB activation during rickettsial infection.
Recent studies have established the importance of IKK complex phosphorylation in the canonical pathway of NF-κB activation in response to a variety of factors, including cytokines, pathogenic bacteria, and viruses (
2,
33,
46). Increased kinase activity of both IKKα and IKKβ as a consequence of
R. rickettsii infection clearly demonstrates modulation of the IKK complex in ECs. Early during the infection, the levels of activation for both kinases were strikingly similar and coincided with the Ser32 phosphorylation of IκBα, an essential signaling step preceding nuclear translocation of NF-κB. Thus, it appears that the early transient phase of
Rickettsia-induced NF-κB activation is mediated by mechanisms involving both IKKα and IKKβ. IKK activation at later times apparently corresponded with the second phase of NF-κB, but only IKKα activity achieved levels comparable to those seen early during the infection. The role of IKKα in the late sustained phase of NF-κB activation, however, is unique in that existing biochemical and genetic evidence indicates that, whereas IKKβ serves as the dominant kinase, IKKα performs a potentially redundant function in stimulus-induced NF-κB activation (
4). It is also possible that NIK (for NF-κB inducing kinase) or some other upstream mitogen-activated protein kinase(s) may be activated, similar to those stimulated by cytokines.
Chlamydia pneumoniae infection of monocytic cells also involves increased activity of IKKα and IκBα/IκB

proteolysis (
6), but the activation of IKKα in this case is transient and does not resemble the pattern seen in our studies. It should be noted that intracellular
R. rickettsii organisms reside and replicate mainly in the host cell cytosol (
8,
42), and studies using a “cell-free” system have documented the ability of viable
R. rickettsii to directly interact with and enhance the DNA-binding activity of NF-κB, which otherwise remains inactive in cytoplasmic extracts isolated from ECs (
31). Such activation of NF-κB occurs in a proteasome-independent fashion and requires a rickettsial protease activity (
31,
32). Thus, it is possible that the second phase of NF-κB activation during infection of intact cells may occur due to the combination of cellular activation of IKKα and enhanced direct interactions between either intracellular rickettsiae or a rickettsial factor with inactive cytoplasmic NF-κB.
The specific interactions of
Rickettsia organisms with the host EC surface to orchestrate the events resulting in IKK/NF-κB activation remain to be elucidated in further detail. Thus far, the identities of a potential host cell receptor or a major rickettsial component(s) serving to trigger the upstream signaling pathways are not known. Initial examination with inactivated
R. rickettsii revealed that the exposure of host cell surface to live bacteria is necessary and a heat-sensitive protein is responsible for the onset of endothelial activation. In
R. rickettsii, the major immunodominant surface-exposed proteins are the outer membrane proteins OmpA and OmpB, of which OmpA is critical for initial adhesion to the host cell membrane (
26). Further investigation of OmpA involvement in infection-induced cell signaling is particularly important in light of the finding that outer membrane proteins of
Bartonella henselae are major pathogenic factors for the production of EC responses (
11). Bacterial LPS is known to be a strong inducer of NF-κB in a variety of cell types (
2,
12). Although it remains a possibility, a potential role for rickettsial LPS is somewhat unlikely considering its significantly lower endotoxin activity in comparison to classically active LPS from
Escherichia coli or
Salmonella spp. (
13) and the existing evidence for noninvolvement in in vitro endothelial responses characterized thus far (
30,
31,
34). Moreover, recent data from our laboratory show that adsorption of LPS by incubation with either polymyxin B-agarose beads (
30) or a monoclonal antibody to
R. rickettsii LPS has no effect on the activation of IKK. A crude preparation of rickettsial LPS, which was much less effective in inducing the expression and activity of tissue factor in cultured ECs as expected, also had no apparent effect on IKK activity, whereas
E. coli (O111:B4) LPS triggered potent induction of both tissue factor and IKK activities (Fig. ) (S. K. Sahni and E. Rydkina, unpublished observations). Another possibility being explored in our laboratory is that
R. rickettsii-induced endothelial signaling, especially late during infection, may be an indirect response due to the production of secondary inducers such as cytokines, e.g., TNF-α or IL-1.
Since NF-κB plays a central role in acute and chronic inflammation, signaling pathways that regulate its activity have become a focal point as molecular targets for the development of new therapeutic compounds (
23). Activation of NF-κB is essential for preventing apoptosis and ensuring the survival of ECs during
R. rickettsii infection and plays an important role in triggering infection-induced responses of the vascular endothelium by stimulating the expression of chemokines IL-8 and monocyte chemoattractant protein 1 (
3; D. R. Clifton, H. Huyck, G. Pryhuber, R. S. Freeman, L. A. Sporn, and S. K. Sahni, Abstr. Am. Soc. Rickettsiol., abstr. 79, p. 58, 2001). Thus, inhibition of IKK and NF-κB by using nonsteroidal anti-inflammatory agents may provide attractive targets for novel antirickettsial therapies. Our data suggest that inhibition of
R. rickettsii-induced activation of IKKα and IKKβ with aspirin or parthenolide is sufficient to effectively attenuate the early transient NF-κB response. This may reduce the ensuing inflammatory reactions and risk of vascular dysfunction associated with rickettsial infections. Sesquiterpene lactones such as parthenolide are amenable for use in treating infections and inflammation of the skin and other organs (
18). Studies have also shown that aspirin exhibits previously unrecognized antibacterial effects mediated by reduction of hematogenous bacterial dissemination and embolism during
Staphylococcus aureus endocarditis (
24) and inhibition of chlamydial growth in human ECs (
47).
In summary, infection of human ECs with viable R. rickettsii induces IKKα and IKKβ activation, an important signaling event which leads to the phosphorylation and proteolysis of IκBα and translocation of active NF-κB dimers to the nucleus. The steady-state expression levels of key NF-κB proteins p65 and p50 and inhibitor protein IκBβ, however, remain relatively unchanged. The anti-inflammatory compounds aspirin and parthenolide inhibit Rickettsia-induced IKK phosphorylation of IκBα and nuclear translocation of NF-κB, suggesting that at least the early signaling occurs through this established pathway. Such action could effectively disrupt the production of NF-κB-dependent inflammatory mediators. These findings thus provide new insights into the molecular basis of NF-κB regulation during R. rickettsii infection and suggest that newly developed specific inhibitors of IKK activity may not only serve as anti-inflammatory agents but also as efficacious therapies to prevent vascular damage and reduce morbidity in human infections.